Drug development in preeclampsia: A 'no go' area?

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue 1, 2012, Pages 50-52

  Everett, Thomas R ^a   Wilkinson, Ian B ^b   Lees, Christoph C ^a  

^a Rosie Maternity Hospital   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

drug development; obstetrics; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CARBON MONOXIDE; CYCLIC GMP; DIGITALIS LIKE FACTOR; DIGOXIN ANTIBODY F(AB) FRAGMENT; DROTRECOGIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM SULFATE; NITRIC OXIDE; PHOSPHODIESTERASE V; PLACEBO; PRAVASTATIN; RELAXIN; S NITROSOGLUTATHIONE; SILDENAFIL; VASCULOTROPIN;

CONFERENCE PAPER; ENDOTHELIAL DYSFUNCTION; HUMAN; MATERNAL HYPERTENSION; MATERNAL MORTALITY; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; SECOND MESSENGER; SEIZURE; SMOOTH MUSCLE RELAXATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PIPERAZINES; PRE-ECLAMPSIA; PREGNANCY; PREMATURE BIRTH; PURINES; S-NITROSOGLUTATHIONE; SULFONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84055176250     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2011.557791     Document Type: Conference Paper

References (19)

1. Hoyert DL.Maternal mortality and related concepts. Vital Health Stat 3 2007;33:1-13.
2. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Siba BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004;190:1590-1595; discussion 1595-1597.
3. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, Simon NP, Wilson DC, Broyles S, Bauer CR, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 2000;105:1216-1226. (Pubitemid 30346889)
4. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth throughout childhood in England and Wales. Pediatrics 2009;123:e312-e327.
5. Wing DA, Powers B, Hickok D. U.S. Food and Drug Administration drug approval: slow advances in obstetric care in the United States. Obstet Gynecol 2010;115:825-833.
6. Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med 2008;5:e22.
7. Sandrim VC, Palei ACT, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008;52:402-407.
8. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649. (Pubitemid 43865232)
9. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361:1511-1517. (Pubitemid 36566342)
10. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN. A randomised, double-blinded, placebocontrolled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:369-382.
11. Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?. Biochem Soc Trans 2009; 37(Pt 6):1237-1242.
12. Adair CD, Luper A, Rose JC, Russell G, Veille JC, Buckalew VM. The hemodynamic effects of intravenous digoxinbinding fab immunoglobulin in severe preeclampsia: a doubleblind, randomized, clinical trial. J Perinatol 2009;29:284-289.
13. Adair CD, Buckalew VM, Graves SW, Lam GK, Johnson DD, Saade G, Lewis DF, Robinson C, Danoff TM, Chauhan N, et al. Digoxin Immune fab treatment for severe preeclampsia. Am J Perinatol 2010;27:655-662.
14. von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, Walley KR, Russell JA. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Crit Care Med 2002;30:1883-1892. (Pubitemid 34879608)
15. Unemori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci 2009;1160:381-384.
16. de Belder A, Lees C, Martin J, Moncada S, Campbell S. Treatment of HELLP syndrome with nitric oxide donor. Lancet 1995;345:124-125.
17. de Belder AJ, MacAllister R, Radomski MW, Moncada S, Vallance PJ. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994;28:691-694. (Pubitemid 24199186)
18. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Duran WN, Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008;103:606-614.
19. Lees C, Langford E, Brown AS, de Belder A, Pickles A, Martin JF, Campbell S. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 1996;88:14-19. (Pubitemid 26197269)